MEDCL (MEDCL) News
Follow MEDCL (MEDCL) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 6 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Medincell Adds €13.8M Loan, Bringing Financing Since July to €41.8M
Medincell secured €13.8M in additional non-dilutive financing from European banks and Bpifrance. Total non-dilutive financing since July 2026 is €41.8M; the loans are on market terms with no equity-linked instruments.
EQUITY | Oct 13, 2026, 05:00 PM UTC
L
Medincell Secures Additional €13.8 Million Non-Dilutive Loan
Medincell says the financing brings its total non-dilutive financing secured since July 2026 to €41.8 million.
EQUITY | Oct 13, 2026, 05:00 PM UTC
M
Medincell Secures Additional EUR 13.8 Million in Non-Dilutive Financing
EQUITY | Oct 13, 2026, 04:13 PM UTC
M
Teva presents positive olanzapine LAI and UZEDY analyses for Medincell
Medincell said partner Teva presented new analyses for investigational olanzapine LAI showing 56% stabilization, 4% relapse post-stabilization, and 21% remission ≥6 months. Medincell also said UZEDY showed favorable cont
EQUITY | Sep 21, 2026, 06:01 AM UTC
L
Medincell to participate in September 2026 investor conferences
Medincell, a commercial- and clinical-stage biopharmaceutical licensing company, said Dr Grace Kim, Chief Strategy Officer, U.S. Finance, will participate in September 2026 investor conferences.
EQUITY | Sep 09, 2026, 04:00 PM UTC
L
Medincell appoints Edna Venneker as Chief Medical Officer
Medincell (Euronext: MEDCL) announced the appointment of Edna Venneker, MD, as Chief Medical Officer.
EQUITY | Sep 01, 2026, 04:00 PM UTC